Novel insights into the implication of the IGF-1 network in prostate cancer.
Nearly a decade has passed since the hypothesis that the insulin-like growth factor (IGF) signalling cascade is involved in prostate carcinogenesis. Recent research has outlined the association of circulating IGF-1 and prostate cancer risk, and studies have elucidated the implication of the IGF network in the early stages of prostate carcinogenesis. Moreover, it has been suggested that IGF-1 induces ligand-independent activation of the androgen receptor and enhances the expression of matrix metalloproteinase-2 and urokinase plasminogen activator. Furthermore, progression to androgen independence has been linked to deregulation of the IGF-1-IGF-1-receptor axis. Here, we report on updated studies that contribute to the unravelling of the IGF 'circuitry' in prostate cancer cells, with the anticipation that relevant pharmacological 'rewiring' might offer novel therapeutic regimens.
Papatsoris
Athanasios G
AG
Department of Biochemistry, School of Medicine, University of Patras, 26110 Patras, Greece.
Karamouzis
Michalis V
MV
Papavassiliou
Athanasios G
AG
D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000502:physiology*; D008297:Male; D011471:Prostatic Neoplasms / Q000209:etiology* / Q000378:metabolism* / Q000628:therapy; D017526:Receptor, IGF Type 1 / Q000502:physiology; D015398:Signal Transduction
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1